Value of high-risk HPV-DNA testing in the triage of ASCUS

References

• Bergström R, Sparen P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer. 1999; 81: 159–66
   PubMed Web of Science ®Google Scholar
• Bergman JB, Sigurdsson JA, Sigurdsson K. What attendance rate can be achieved for Pap smear screening? A case-control study on the characteristics of non-attenders and results of reminder efforts. Scand J Prim Health Care. 1996; 14: 152–8
   PubMed Web of Science ®Google Scholar
• Jansson A, Gustafsson M, Wilander E. Efficiency of cytological screening for detection of cervical squamous carcinoma. A study in the county of Uppsala 1991–1994. Ups J Med Sci 1998; 103: 147–54
   PubMed Web of Science ®Google Scholar
• Lindqvist PG, Hellsten C, Rippe A. Screening history of women in Malmö with invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol. 2008; 137: 77–83
   PubMed Web of Science ®Google Scholar
• Andrae B, Kemetli L, Sparén P, Silfverdal L, Strander B, Ryd W, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008; 100: 605–6
   PubMedGoogle Scholar
• zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology. 1991; 184: 9–13
   PubMed Web of Science ®Google Scholar
• Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12–9
   PubMed Web of Science ®Google Scholar
• Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87: 796–802
   PubMed Web of Science ®Google Scholar
• Clavel C, Masure M, Bory JP, Putaud I, Mamgeonjean C, Lotenzato M, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer. 2001; 89: 1616–23
   Web of Science ®Google Scholar
• Bory J, Cucherousset J, Lorenzato M, Gabiel R, Quereux C, Birembaut P, et al. Recurrent human papillomavirus infection detected with the hybrid capture 2 assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer. 2002; 102: 519–25
   PubMed Web of Science ®Google Scholar
• Petry K, Menton S, Menton M, van Loenen-Frosch F, de carvalho Gomes H, Holz B, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer. 2003; 88: 1570–7
   PubMed Web of Science ®Google Scholar
• Andersson S, Dillner L, Elfgren K, Mints M, Persson M, Rylander E. A comparison of the human papillomavirus test and papanicolaou smear as a second screening method for women with minor cytological abnormalities. Acta Obstet Gynecol Scand. 2005; 84: 996–1000
   PubMed Web of Science ®Google Scholar
• Gustafsson L, Sparen P, Gustafsson M, Pettersson B, Wilander E, Bergstrom R, et al. Low efficiency of cytologic screening for cancer in situ of the cervix in older women. Int J Cancer. 1995; 63: 804–9
   PubMed Web of Science ®Google Scholar
• Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009; 124: 516–20
   PubMed Web of Science ®Google Scholar
• Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009; 101: 88–99
   PubMedGoogle Scholar
• Andrae B, Smith P. Clinical impact of quality assurance in an organized cervical screening program. Acta Obstet Gynecol Scand. 1999; 78: 429–35
   PubMed Web of Science ®Google Scholar
• Forslund O, Antonsson A, Edlund K, van der Brule AJ, Hansson BJ, Meijer CJ, et al. Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol 2002; 67: 535–41
   Web of Science ®Google Scholar
• DM Parkin, Whelan, SL, Ferlay, J, Cancer incidence in five continents, vol. VII. LyonFrance: IARC Scientific Publications; 1997.
   Google Scholar
• Melkert PW, Hopman E, van den Brule AJ, Risse EK, van Diest PJ, Bleker OP, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer. 1993; 53: 919–23
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009; 360: 1453–5
   PubMed Web of Science ®Google Scholar
• Solomon D, Schiffman M, Tarone R. ALTS Study group comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001; 93: 293–9
   PubMed Web of Science ®Google Scholar